Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Nov 21, 2022 7:07pm
168 Views
Post# 35117106

RE:RE:Cantor report effect

RE:RE:Cantor report effectChill Biobob. Cantor's report was a nice step in the right direction but Cantor services mostly institutional investors and they really can't buy THTX in the open market due to the low market cap and low traidng volue. So, its impact is more psychological than anything else until a deal is done, at which point Cantor's clients might well be part of it since they could grab big chunks of stock in one fell swoop. Meanwhile, the mere fact that Cantor chose now to write the report is a good indicator that TH  is expecting good news on something, most likely TH-1902, that will lead to a deal coming to market before too much longer. So, it is a leading indicator of good news on the horizon.

If there is a deal on the horizon (and Cantor's report noted TH would need to raise money), there is a good chance other brokers will also suddenly become interested in TH. Investment bankers are starving right now due to deal flow plummeting in the bear market, so TH might see a flock of analysts suddenly becoming interested in it as they make an effort to get part of the offering and earn some fee income.

But you are right, the stock will not likely have a big move higher until TH produces some good news on cancer or NASH (or both). Analyst reports will help create new buying interest, which will help the stock (especially since quite a lot of shares are locked up in long term holders accounts), but news is the only thing that can drive it significantly and sustainably higher. Cantor's report is a good indicator we are going to get that news in the months ahead but, until good news is out, the stock will still be bouncing around a lot, maybe with a postive bias, but it is not likely to double or triple based off of analyst hopes for some significant revenues in NASH later this decade (which is what si behind Cantor's $9 prce target). 

Biobob wrote: I mean some high profile analyst from NYC just told us Th is worth 12$ cdn and this is what we get 50 cents uptick and then it's back to same sh.t.  Honestly we're fuc..ed until they deliver something material.


<< Previous
Bullboard Posts
Next >>